sensei(SNSE) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, MA – August 06, 2024 – Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the disc ...